## GOVERNMENT OF INDIA MINISTRY OF CHEMICALS AND FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

#### **LOK SABHA**

### **UNSTARRED QUESTION No. 1521**

## TO BE ANSWERED ON THE 25th July, 2017

#### **Drugs under Price Control**

#### 1521. SHRI RAJESH KUMAR DIWAKER:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether more drugs are proposed to be brought under price control in the current year;
- (b) if so, the details thereof including the total number of medicines already under price control;
- (c) the time-line fixed therefor; and
- (d) whether the existing mechanism for monitoring the retail prices of medicines is working effectively and if so, the details thereof?

#### **ANSWER**

# MINISTER OF STATE IN THE MINISTRY OF ROAD TRANSPORT AND HIGHWAYS; MINISTRY OF SHIPPING AND MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI MANSUKH L. MANDAVIYA)

- (a) & (b): All drugs in the National List of Essential Medicines (NLEM) are included in Schedule-1 of the Drugs (Prices Control) Order, 2013 (DPCO-2013) and their prices are controlled. If there are any additions in the NLEM during the current year, those drugs will be brought under price control. From 29.03.2016 to 30.6.2017, the Government has fixed the ceiling prices of 761 formulations (including 2 coronary stents).
- (c): As per Para 17 of DPCO, 2013, the ceiling price(s) for medicine(s), added in the Schedule-1 shall be fixed as per the provisions of DPCO,2013 within a period of sixty days from the date of notification.
- (d): The Government monitors the maximum retail prices (MRP) of all the medicines, including the non-scheduled formulations, and ensures that no manufacturer increases the maximum retail price of non-scheduled formulations by more than ten percent of the maximum retail price during preceding twelve months. Annual revision in the prices of scheduled formulations is permissible to the extent of change in the Wholesale Price Index (WPI) for the particular year. The Government is effectively monitoring the prices of scheduled medicines and takes action against companies found to be overcharging the consumers.